Myogen Inc.'s lead product, enoximone, missed statistical significance in the primary endpoint of a Phase III trial to support an ongoing pair of other, pivotal Phase III studies - but the company said success in secondary endpoints means the study's objective was achieved. (BioWorld Today)

In Greek mythology, Chiron was a centaur associated with healing - not a bad figure for a biotechnology firm to hook itself up with. But in the industry, what is Chiron Corp. known for? Quickly, now.

"Toll-like receptor" sounds like a cop waiting at a highway coin basket to catch those who pass through without paying. And, in a way, that's what toll-like receptors, or TLRs, are. (BioWorld Financial Watch)